Applying Stem Cell Technology to Liver Diseases

[Guest guest]

http://www.sciencedaily.com/releases/2010/08/100825131542.htm

Applying Stem Cell Technology to Liver Diseases

ScienceDaily (Aug. 26, 2010) — Great excitement greeted the discovery a few

years ago that certain cells from mice and humans could be reprogrammed to

become inducible pluripotent stem cells (iPS cells), as they hold promise for

cell replacement therapy and modeling human disease.

Two independent research groups -- one led by Ludovic Vallier, at the University

of Cambridge, United Kingdom, and the other led by Holger Willenbring, at the

University of California San Francisco -- have now shown that both possibilities

are true for iPS cell-derived liver cells known as hepatocytes.

In the first study, Vallier and colleagues generated iPS cells from patients

with various inherited diseases of the liver. These cells were then cultured in

a defined way to generate hepatocytes, which were found to recapitulate key

features of the diseases affecting the patients from which they were derived.

While this study indicates that iPS cells can be used to model diseases of the

liver, Willenbring and colleagues showed that iPS cell-derived hepatocytes have

both the functional and proliferative capabilities needed for liver regeneration

in mice.

In an accompanying commentary, Greenbaum, at Jefferson University

School of Medicine, Philadelphia, describes how these studies have extended our

understanding of the potential for iPS cells to be used for cell replacement

therapy and modeling human disease.

Email or share this story:| More

--------------------------------------------------------------------------------

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff)

from materials provided by Journal of Clinical Investigation, via EurekAlert!, a

service of AAAS.

--------------------------------------------------------------------------------

Journal References:

1.Silvia Espejel, Garrett R. Roll, K. Mclaughlin, Y. Lee, Y.

Zhang, J. Laird, Keisuke Okita, Shinya Yamanaka, and Holger Willenbring.

Induced pluripotent stem cell–derived hepatocytes have the functional and

proliferative capabilities needed for liver regeneration in mice. J Clin Invest,

August 25, 2010 DOI: 10.1172/JCI43267

2.S. Tamir Rashid, Sebastien Corbineau, Nick Hannan, Stefan J. Marciniak, Elena

Miranda, Graeme , Isabel Huang-Doran, n , Lars

Ahrlund-Richter, Skepper, Semple, Anne Weber, A. Lomas,

Ludovic Vallier. Modeling inherited metabolic disorders of the liver using human

induced pluripotent stem cells. Journal of Clinical Investigation, 25 August

2010 DOI: 10.1172/JCI43122

[Guest guest]

http://www.sciencedaily.com/releases/2010/08/100825131542.htm

Applying Stem Cell Technology to Liver Diseases

ScienceDaily (Aug. 26, 2010) — Great excitement greeted the discovery a few

years ago that certain cells from mice and humans could be reprogrammed to

become inducible pluripotent stem cells (iPS cells), as they hold promise for

cell replacement therapy and modeling human disease.

Two independent research groups -- one led by Ludovic Vallier, at the University

of Cambridge, United Kingdom, and the other led by Holger Willenbring, at the

University of California San Francisco -- have now shown that both possibilities

are true for iPS cell-derived liver cells known as hepatocytes.

In the first study, Vallier and colleagues generated iPS cells from patients

with various inherited diseases of the liver. These cells were then cultured in

a defined way to generate hepatocytes, which were found to recapitulate key

features of the diseases affecting the patients from which they were derived.

While this study indicates that iPS cells can be used to model diseases of the

liver, Willenbring and colleagues showed that iPS cell-derived hepatocytes have

both the functional and proliferative capabilities needed for liver regeneration

in mice.

In an accompanying commentary, Greenbaum, at Jefferson University

School of Medicine, Philadelphia, describes how these studies have extended our

understanding of the potential for iPS cells to be used for cell replacement

therapy and modeling human disease.

Email or share this story:| More

--------------------------------------------------------------------------------

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff)

from materials provided by Journal of Clinical Investigation, via EurekAlert!, a

service of AAAS.

--------------------------------------------------------------------------------

Journal References:

1.Silvia Espejel, Garrett R. Roll, K. Mclaughlin, Y. Lee, Y.

Zhang, J. Laird, Keisuke Okita, Shinya Yamanaka, and Holger Willenbring.

Induced pluripotent stem cell–derived hepatocytes have the functional and

proliferative capabilities needed for liver regeneration in mice. J Clin Invest,

August 25, 2010 DOI: 10.1172/JCI43267

2.S. Tamir Rashid, Sebastien Corbineau, Nick Hannan, Stefan J. Marciniak, Elena

Miranda, Graeme , Isabel Huang-Doran, n , Lars

Ahrlund-Richter, Skepper, Semple, Anne Weber, A. Lomas,

Ludovic Vallier. Modeling inherited metabolic disorders of the liver using human

induced pluripotent stem cells. Journal of Clinical Investigation, 25 August

2010 DOI: 10.1172/JCI43122

[Guest guest]

http://www.sciencedaily.com/releases/2010/08/100825131542.htm

Applying Stem Cell Technology to Liver Diseases

ScienceDaily (Aug. 26, 2010) — Great excitement greeted the discovery a few

years ago that certain cells from mice and humans could be reprogrammed to

become inducible pluripotent stem cells (iPS cells), as they hold promise for

cell replacement therapy and modeling human disease.

Two independent research groups -- one led by Ludovic Vallier, at the University

of Cambridge, United Kingdom, and the other led by Holger Willenbring, at the

University of California San Francisco -- have now shown that both possibilities

are true for iPS cell-derived liver cells known as hepatocytes.

In the first study, Vallier and colleagues generated iPS cells from patients

with various inherited diseases of the liver. These cells were then cultured in

a defined way to generate hepatocytes, which were found to recapitulate key

features of the diseases affecting the patients from which they were derived.

While this study indicates that iPS cells can be used to model diseases of the

liver, Willenbring and colleagues showed that iPS cell-derived hepatocytes have

both the functional and proliferative capabilities needed for liver regeneration

in mice.

In an accompanying commentary, Greenbaum, at Jefferson University

School of Medicine, Philadelphia, describes how these studies have extended our

understanding of the potential for iPS cells to be used for cell replacement

therapy and modeling human disease.

Email or share this story:| More

--------------------------------------------------------------------------------

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff)

from materials provided by Journal of Clinical Investigation, via EurekAlert!, a

service of AAAS.

--------------------------------------------------------------------------------

Journal References:

1.Silvia Espejel, Garrett R. Roll, K. Mclaughlin, Y. Lee, Y.

Zhang, J. Laird, Keisuke Okita, Shinya Yamanaka, and Holger Willenbring.

Induced pluripotent stem cell–derived hepatocytes have the functional and

proliferative capabilities needed for liver regeneration in mice. J Clin Invest,

August 25, 2010 DOI: 10.1172/JCI43267

2.S. Tamir Rashid, Sebastien Corbineau, Nick Hannan, Stefan J. Marciniak, Elena

Miranda, Graeme , Isabel Huang-Doran, n , Lars

Ahrlund-Richter, Skepper, Semple, Anne Weber, A. Lomas,

Ludovic Vallier. Modeling inherited metabolic disorders of the liver using human

induced pluripotent stem cells. Journal of Clinical Investigation, 25 August

2010 DOI: 10.1172/JCI43122

[Guest guest]

http://www.sciencedaily.com/releases/2010/08/100825131542.htm

Applying Stem Cell Technology to Liver Diseases

ScienceDaily (Aug. 26, 2010) — Great excitement greeted the discovery a few

years ago that certain cells from mice and humans could be reprogrammed to

become inducible pluripotent stem cells (iPS cells), as they hold promise for

cell replacement therapy and modeling human disease.

Two independent research groups -- one led by Ludovic Vallier, at the University

of Cambridge, United Kingdom, and the other led by Holger Willenbring, at the

University of California San Francisco -- have now shown that both possibilities

are true for iPS cell-derived liver cells known as hepatocytes.

In the first study, Vallier and colleagues generated iPS cells from patients

with various inherited diseases of the liver. These cells were then cultured in

a defined way to generate hepatocytes, which were found to recapitulate key

features of the diseases affecting the patients from which they were derived.

While this study indicates that iPS cells can be used to model diseases of the

liver, Willenbring and colleagues showed that iPS cell-derived hepatocytes have

both the functional and proliferative capabilities needed for liver regeneration

in mice.

In an accompanying commentary, Greenbaum, at Jefferson University

School of Medicine, Philadelphia, describes how these studies have extended our

understanding of the potential for iPS cells to be used for cell replacement

therapy and modeling human disease.

Email or share this story:| More

--------------------------------------------------------------------------------

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff)

from materials provided by Journal of Clinical Investigation, via EurekAlert!, a

service of AAAS.

--------------------------------------------------------------------------------

Journal References:

1.Silvia Espejel, Garrett R. Roll, K. Mclaughlin, Y. Lee, Y.

Zhang, J. Laird, Keisuke Okita, Shinya Yamanaka, and Holger Willenbring.

Induced pluripotent stem cell–derived hepatocytes have the functional and

proliferative capabilities needed for liver regeneration in mice. J Clin Invest,

August 25, 2010 DOI: 10.1172/JCI43267

2.S. Tamir Rashid, Sebastien Corbineau, Nick Hannan, Stefan J. Marciniak, Elena

Miranda, Graeme , Isabel Huang-Doran, n , Lars

Ahrlund-Richter, Skepper, Semple, Anne Weber, A. Lomas,

Ludovic Vallier. Modeling inherited metabolic disorders of the liver using human

induced pluripotent stem cells. Journal of Clinical Investigation, 25 August

2010 DOI: 10.1172/JCI43122